Allogeneic bone marrow transplantation for systemic AL amyloidosis

Area of Science:

• Hematology
• Oncology
• Transplantation

Background:

• AL amyloidosis is a plasma cell disorder characterized by amyloid deposit accumulation.
• Low-intensity chemotherapy often proves ineffective due to the slow regression of amyloid deposits.
• Clinical benefit typically necessitates suppression of the underlying plasma cell dyscrasia.

Observation:

• A patient with AL amyloidosis underwent allogeneic bone marrow transplant (allo-BMT).
• The patient achieved complete clinical recovery three years post-transplant.

Findings:

• This case represents the first successful allo-BMT for AL amyloidosis.
• The successful outcome suggests allo-BMT can induce significant clinical improvement.

Implications:

• Allogeneic bone marrow transplant is a viable and effective treatment option for AL amyloidosis.
• A potential therapeutic window for dose-intensive chemotherapy may exist in AL amyloidosis patients.
• Further research into optimal treatment timing and intensity for AL amyloidosis is warranted.